Kura Oncology (NASDAQ:KURA) Given "Buy" Rating at HC Wainwri

HC Wainwright reaffirmed their buy rating on shares of Kura Oncology (NASDAQ:KURA – Free Report) in a report released on Wednesday, Benzinga reports. The firm currently has a $32.00 target price on the stock. A number of other equities analysts also recently commented on the company. JMP Securities increased their price objective on Kura Oncology […]

Related Keywords

Switzerland , United States , Swiss , Troy Edward Wilson , Thomas James Doyle , Nasdaq , York Mellon Corp , Jupiter Asset Management Ltd , Franklin Resources Inc , Charles Schwab Investment Management Inc , Swiss National Bank , Kura Oncology Inc , Kura Oncology , Free Report , Moderate Buy , Get Free Report , Edward Wilson , James Doyle , New York Mellon Corp , Schwab Investment Management , Asset Management , National Bank , Lysinek Specific Methyltransferase , Kura Oncology Daily ,